Dexcel Pharma Technologies Ltd.
Known title: 10% OwnerCIK: 0001720007
Dexcel Pharma Technologies Ltd.'s purchase track record
Dexcel Pharma Technologies Ltd. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/10/2022 | ROIV | $20.00M | +49.8% | +74.7% | +4.4% |
| 4/22/2022 | ROIV | $155K | +10.0% | +13.6% | -12.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ROIV | ▲ Buy | Open Market | 4,000,000 | $20.0M | 11/10/2022 | View on chart |
| ROIV | ▲ Buy | Open Market | 8,600 | $34K | 4/25/2022 | View on chart |
| ROIV | ▲ Buy | Open Market | 31,685 | $121K | 4/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Roivant Sciences receives downgrades from Wolfe Research and analyst
Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.
Roivant Sciences receives downgrades from Wolfe Research and analyst. Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.